PBAC's latest decision on Polyethylene glycol 400 with propylene glycol: Recommended (2025). Considered for Treatment of severe dry eye syndrome. Specifically, a new 28 x 0.8 mL unit dose pack size requested on a cost-minimisation basis versus the currently listed 30-pack.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2021
Submissions
3
2021 → 2025
Eligible population
Adults with severe dry eye syndrome, particularly those sensitive to preservatives in multi-dose eye drops.
Therapy area
Ophthalmology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Systane 30 x 0.8 mL unit dose pack
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. This is a Category 4 submission (pack size formulation change) with equi-effective dosing (1:1).